Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27734872 | 0.98 | GAA (0.48) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL17144690 | 0.95 | FAAH (0.53) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL11194747 | 0.91 | FAAH (0.56) | FAAHCES2ALDH1A1PLA2G4BATM | |
| SCHEMBL7892333 | 0.89 | GAA (0.50) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL129596 | 0.89 | GAA (0.54) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL7892352 | 0.86 | GAA (0.47) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL2601411 | 0.85 | CES2 (0.47) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL546058 | 0.84 | CES2 (0.50) | MGAMGAASIMGAM2CES2 | |
| SCHEMBL11385627 | 0.84 | GAA (0.64) | MGAMGAASIMGAM2FAAH | |
| SCHEMBL18256120 | 0.84 | GAA (0.48) | MGAMGAASIMGAM2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9815835-B2 | Substituted polycyclic carbamolypyridone derivative | SHIONOGI & CO., LTD. (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9802959-B2 | Method of producing (4R,12aS)-7,9-dihalo-4-methyl-3,4,12,12a-tetrahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-6,8-diones | SHIONOGI & CO., LTD. (JP) | 2017-10-31 | — | — | US | disclosed |
| US-9758515-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20170240564-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-9650394-B2 | Methods of producing substituted (3S,11aR)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides | SHIONOGI & CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-3127908-A2 | PROCESS FOR PREPARING COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20160368921-A1 | SUBSTITUTED POLYCYCLIC CARBAMOLYPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2016-12-22 | — | — | US | disclosed |
| US-9505783-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-8865907-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-20140011995-A1 | Process for Preparing Compound Having HIV Integrase Inhibitory Activity | SHINOGI & CO., LTD (JP) | 2014-01-09 | — | — | US | disclosed |
| EP-2620436-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | Shionogi&Co., Ltd. (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2444400-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| WO-2007051062-A2 | SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-4414400-A | FROM 4-HALOACETOACETIC ESTER, CYCLIZING ETHER CLEAVAGE OF 4-TERT-BUTOXYACETOACETIC ESTER | LONZA LTD. (CH) | 1983-11-08 | — | — | US | disclosed |
| US-4020178-A | 1,4-Dihydropyridine esters used as coronary dilators and anti-hypertensives | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-26 | — | — | US | disclosed |
| US-3974278-A | 1,4-Dihydropyridine esters | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3971796-A | 1,4-Dihydropyridine esters | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368921-A1 | SUBSTITUTED POLYCYCLIC CARBAMOLYPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | MGAM 1475/4885GAA 922/4885SI 1045/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | MGAM 1427/4885GAA 950/4885SI 1009/4885 |
| US-20170240564-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, DRD4, PYM1 | MGAM 3310/4885GAA 2510/4885SI 2135/4885 |
| US-20140011995-A1 | Process for Preparing Compound Having HIV Integrase Inhibitory Activity | DRD4, XDH, CCND2 | MGAM 3087/4885GAA 2421/4885SI 1733/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | MGAM 1649/4885GAA 1254/4885SI 416/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | MGAM 103/4885GAA 354/4885SI 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.